Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 4, 2008, Pages 460-462

  De Boer Van Der Kolk, I Marion ^a   Sprangers, Mirjam A G ^a   Van Der Ende, Marchina ^b   Schreij, Gerrit ^c   De Wolf, Frank ^d   Nieuwkerk, Pythia T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; HEALTH BELIEF; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NEEDS ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; VIRAL LOAD;

EID: 57649126305     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318186eefe     Document Type: Letter

References (10)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
2. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161:1962-1968.
3. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41:285-297.
4. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23-S35.
5. Gauchet A, Tarquinio C, Fischer G. Psychosocial predictors of medication adherence among persons living with HIV. J Behav Med. 2007;14:141-150.
6. Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34:46-55.
7. Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38-44.
8. Horne R, Cooper V, Gellaitry G, et al. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45:334-341.
9. Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med. 2003;138:680-681.
10. Pogany K, van Valkengoed IG, Prins JM, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm 3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr. 2007;44:395-400.